Capricor Therapeutics Inc (NASDAQ:CAPR) Given Average Rating of “Buy” by Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $34.50.

A number of brokerages recently commented on CAPR. HC Wainwright restated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Cantor Fitzgerald raised their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CAPR. SG Americas Securities LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at about $133,000. Oppenheimer & Co. Inc. grew its position in shares of Capricor Therapeutics by 25.2% in the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after purchasing an additional 13,762 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $161,000. FMR LLC purchased a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $370,000. Finally, BNP Paribas Financial Markets raised its position in shares of Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 15,872 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Trading Up 0.4 %

Shares of CAPR opened at $15.15 on Friday. The company’s 50-day moving average price is $14.20 and its 200 day moving average price is $13.20. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40. The firm has a market cap of $688.87 million, a P/E ratio of -14.29 and a beta of 4.08.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.